What does bioequivalence mean?

Bioequivalence means that two drug products show no significant difference in absorption and therapeutic effect when given under the same conditions.

What is the difference between bioavailability and bioequivalence?

Bioavailability refers to the extent and rate at which an active ingredient becomes available in the body. Bioequivalence compares the bioavailability of two products to ensure they are effectively the same.

What is the difference between bioequivalence and biosimilars?

Bioequivalence applies to generic small-molecule drugs. Biosimilars are biologic medicines, which require more complex comparability studies, not just bioequivalence testing.

What are FDA bioequivalence requirements?

The FDA requires generics submitted under ANDA to demonstrate bioequivalence to the reference drug. This is done through pharmacokinetic studies, sometimes supported by in vitro testing.

What is product-specific bioequivalence guidance?

The FDA issues product-specific guidance documents that outline the exact requirements for demonstrating equivalence for individual drug products.

What is bioequivalence in pharmacology?

In pharmacology, bioequivalence refers to how two formulations of a drug behave similarly in the body. While widely studied in academia, in the pharmaceutical industry it is primarily applied in the regulatory approval of generics.

What is bioequivalence?

Bioequivalence refers to the scientific demonstration that two drug products – typically a generic and its reference (innovator) product – show no significant difference in the rate and extent of drug absorption when administered at the same molar dose under similar conditions. In simple terms, bioequivalence means that the generic drug behaves in the body in the same way as the original, delivering the same therapeutic effect. Regulators such as the FDA and EMA require comprehensive bioequivalence studies as part of the approval process for generic products. Without proof of bioequivalence, a generic drug cannot be authorized for sale. Key points of bioequivalence: It focuses on drug absorption and bioavailability. It is typically assessed using pharmacokinetic endpoints such as Cmax (maximum plasma concentration), Tmax (time to reach Cmax), and AUC (area under the plasma concentration-time curve). Bioequivalence ensures that patients can safely switch from a branded drug to its generic equivalent without differences in efficacy or safety.

Home / How we can help / Particle characterization

Solid state characterization of pharmaceuticals

Risk mitigation – comprehensive product characterization

Understanding the solid-state properties of pharmaceutical materials is essential for ensuring drug safety, efficacy, and regulatory compliance. The physical form of an active pharmaceutical ingredient (API), excipient or finished drug product – whether crystalline, polymorphic, or amorphous – has a direct impact on solubility, dissolution rate, stability, and ultimately on the therapeutic performance of the drug product.

At Particle Analytical, we specialize in solid state characterization of pharmaceuticals, providing a comprehensive range of analytical techniques under GMP certification. By applying advanced solid state characterization techniques, we help pharmaceutical companies understand and control the critical quality attributes of their products, supporting development, manufacturing, and regulatory approval.

Why solid state characterization matters in pharmaceuticals

Solid-state characterization refers to the analysis of the physical and structural properties of pharmaceutical solids, including APIs, excipients, and finished products. Unlike chemical assays that measure composition, solid-state techniques focus on the crystalline structure, particle morphology, polymorphism, and other physical attributes that influence how a drug behaves in the body.

Solid-state characterization of pharmaceuticals plays a vital role in understanding:

Polymorphic transitions and stability.
Crystalline vs. amorphous content.
Particle size distribution and morphology.
Drug-excipient interactions.
Dissolution and bioavailability.

By investigating these properties, scientists can ensure that drug formulations remain safe, stable, and effective throughout their lifecycle.

Why reverse engineering matters

The solid state characterization of pharmaceuticals is essential at every stage of drug development.

During discovery and preclinical development, characterization ensures that the most stable and bioavailable form of an API is selected. In clinical development, it provides data for regulatory submissions and supports Quality by Design (QbD) approaches. In manufacturing, solid-state techniques monitor batch consistency, detect polymorphic transitions, and ensure compliance with GMP standards.

Without robust solid-state analysis, pharmaceutical companies risk stability failures, reduced efficacy, or regulatory setbacks.

Solid state characterization techniques

A wide range of solid state characterization techniques are used to analyze pharmaceutical materials. At Particle Analytical, we provide access to state-of-the-art instrumentation and methods, including:

X-ray powder diffraction (XRPD)

XRPD is the gold standard for identifying polymorphs, determining crystallinity, and distinguishing between different solid forms. It is essential for phase identification and stability studies.

Raman spectroscopy and Raman confocal microscopy

Raman analysis provides molecular fingerprints and allows mapping of polymorphs, contaminants, and amorphous content. When combined with Morphologically Directed Raman Spectroscopy (MDRS), it offers powerful insights into particle size, shape, and composition – supporting bioequivalence studies, even for complex products such as inhalation powders, nasal sprays, and suspensions.

Laser diffraction

Laser diffraction measures particle size distribution across a wide range, providing critical data for formulation performance, dissolution rate prediction, and inhalation product optimization.

Differential scanning calorimetry (DSC)

DSC measures thermal properties, such as melting points, phase transitions, and glass transition temperatures. It is invaluable for studying polymorphism, crystallinity, and stability under temperature stress.

Scanning electron microscopy (SEM) and SEM-EDX

SEM provides high-resolution imaging of particle morphology, while SEM-EDX adds elemental analysis for identifying contaminants or inorganic components.

BET surface area analysis

Surface area measurements are critical for dissolution and bioavailability. Together with particle size, BET analysis determines how drug particles interact with biological environments.

These complementary techniques allow for a complete picture of a material’s physical form, stability, and performance.

Advantages of solid state characterization

Pharmaceutical companies that invest in solid-state characterization benefit from improved drug stability, optimized formulations, and reduced development risks. It allows faster regulatory approval by providing reliable, validated data and supports manufacturing by ensuring batch-to-batch consistency.

With Particle Analytical’s expertise, companies gain confidence that their products meet the highest scientific and regulatory standards.

Challenges in solid state characterization

Despite its importance, solid state characterization can be challenging. Some APIs are metastable or exist in multiple polymorphic forms. Amorphous materials may crystallize during storage, altering drug performance. Environmental factors such as humidity and temperature can induce transitions that affect stability.

Our laboratory addresses these challenges using advanced instrumentation and GMP-validated methods, ensuring accurate and reproducible results even for complex materials.

Regulatory context of solid state characterization

Regulatory agencies such as the FDA and EMA require comprehensive data on solid-state properties as part of drug approval processes. Polymorphism, crystallinity, and particle size are considered Critical Quality Attributes (CQAs) that directly impact safety and efficacy.

Solid state characterization is also central to ICH guidelines, including ICH Q6A, which highlights the need for thorough testing of physical and chemical properties. By outsourcing these studies to a GMP-certified laboratory, companies ensure that their data is audit-ready and aligned with international standards.

Applications of solid state characterization in pharma

Solid state characterization supports pharmaceutical development and production in multiple ways.

Selecting the Most Stable Polymorph

It ensures that the most stable polymorphic form is selected during early development.

Detecting and Quantifying Amorphous Content

It helps detect and quantify amorphous content, which can affect solubility and stability.

Characterizing Excipient Interactions

It characterizes excipient interactions and ensures compatibility in formulations.

Supporting Bioequivalence studies

It supports bioequivalence studies for generics, particularly for inhalation products, nasal sprays, and suspensions.

Providing Data for Regulatory Compliance

It provides essential data for regulatory submissions, ensuring compliance with ICH, FDA, and EMA requirements.

Frequently asked questions about solid state characterization

What is solid state characterization of pharmaceuticals?

It is the analysis of the physical and structural properties of drug substances and products, including polymorphism, crystallinity, particle size, and morphology.

Why is solid state characterization important?

It ensures stability, bioavailability, and regulatory compliance, reducing risks during development and manufacturing.

What are solid state characterization techniques?

Key techniques include XRPD, Raman spectroscopy, laser diffraction, DSC, SEM, BET surface area analysis, DLS for nanosized particles, and LOPC for subvisible particle characterization. These methods provide complementary data on structure, morphology, and stability.

When is solid state characterization required?

At every stage of drug development – from early screening and formulation design to regulatory submissions and commercial manufacturing.

Can solid state characterization detect contaminants?

Yes. Techniques such as Raman spectroscopy, SEM-EDX, optical microscopy and XRPD can identify contaminants or unexpected crystalline phases.

Partner with Particle Analytical

At Particle Analytical, we combine advanced instrumentation with regulatory expertise to deliver comprehensive solid state characterization of pharmaceuticals. Our GMP-certified laboratory provides accurate and reproducible data to support development, quality control, and regulatory approval.

Whether you need polymorphism studies, crystallinity measurements, particle size analysis, or full characterization of complex formulations, we are ready to assist. The process is simple: ship your samples, and we return a detailed report with reliable, regulatory-compliant results.

Contact us today to discuss your project or request a quote for solid state characterization services.